These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 30626376)

  • 21. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
    Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
    Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
    Holden SE; Currie CJ; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
    Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
    Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.
    Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y
    BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluocinolone acetonide for the treatment of diabetic macular edema.
    Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
    Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
    Cunha-Vaz J; Ashton P; Iezzi R; Campochiaro P; Dugel PU; Holz FG; Weber M; Danis RP; Kuppermann BD; Bailey C; Billman K; Kapik B; Kane F; Green K;
    Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Anatomical and Functional Outcomes of Intravitreal Dexamethasone Implant between Phakic and Pseudophakic Eyes with Diabetic Macular Edema.
    Kaldırım H; Savur F; Kırgız A; Atalay K
    Korean J Ophthalmol; 2020 Oct; 34(5):383-391. PubMed ID: 33099560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
    Massa H; Nagar AM; Vergados A; Dadoukis P; Patra S; Panos GD
    J Int Med Res; 2019 Jan; 47(1):31-43. PubMed ID: 30556449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
    Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
    Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ILUVIEN
    Teixeira C; Pessoa B; Ruão M; Sousa JPC; Penas S; Silva R; Carneiro Â; Meireles A
    Eur J Ophthalmol; 2024 Jul; 34(4):1149-1158. PubMed ID: 38013451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
    Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
    Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
    Soubrane G; Behar-Cohen F
    J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN
    Mushtaq Y; Mushtaq MM; Gatzioufas Z; Ripa M; Motta L; Panos GD
    Drug Des Devel Ther; 2023; 17():961-975. PubMed ID: 37020801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study.
    Ruiz-Moreno JM; Adán A; Lafuente M; Asencio Durán M; Arias Barquet L; García Layana A; Araiz Iribarren J
    Int Ophthalmol; 2023 Dec; 43(12):4639-4649. PubMed ID: 37697082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
    Adams OE; Schechet SA; Hariprasad SM
    Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
    Elbarky AM
    Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.